Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

If You Use a Screen Reader

This content is available through Read Online (Free) program, which relies on page scans. Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.

Sulpiride And The Potentiation Of Progestogen Only Contraception

M. R. Payne, P. W. Howie, A. S. McNeilly, W. Cooper, M. Marnie and L. Kidd
British Medical Journal (Clinical Research Edition)
Vol. 291, No. 6495 (Aug. 31, 1985), pp. 559-561
Published by: BMJ
Stable URL: http://www.jstor.org/stable/29520393
Page Count: 3
  • Read Online (Free)
  • Subscribe ($19.50)
  • Cite this Item
Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
Sulpiride And The Potentiation Of Progestogen Only Contraception
Preview not available

Abstract

A progestogen (norethisterone) and a dopamine antagonist (sulpiride) were given alone and in combination to volunteers to examine their effects on excretion of ovarian steroids. Compared with non-treatment cycles (n=15), contraception with a progestogen alone (n=10) was associated with increased excretion of oestrone and partial suppression of excretion of pregnanediol, suggesting partial luteinisation of unruptured follicles. By contrast, the combination of norethisterone and sulpiride (n=9) suppressed both ovarian steroids to basal values, the suppression being even greater than with sulpiride alone (n=5). These results suggest that a combination of a progestogen with a dopamine antagonist might have a role in contraception.

Page Thumbnails

  • Thumbnail: Page 
559
    559
  • Thumbnail: Page 
560
    560
  • Thumbnail: Page 
561
    561